(FHTX) –
-
Form 4 Foghorn Therapeutics For: Apr 16 Filed by: Humer Kristian
-
Form 3 Foghorn Therapeutics For: Apr 16 Filed by: Humer Kristian
-
Form 8-K Foghorn Therapeutics For: Apr 16
-
Foghorn Therapeutics (FHTX) Announces Appointment of Kristian Humer as Chief Financial Officer
-
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
-
Form 8-K Foghorn Therapeutics For: Apr 09
-
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
-
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
-
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
-
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
-
Form 4 Foghorn Therapeutics For: Mar 11 Filed by: Cavalie Fanny
-
Form 8-K Foghorn Therapeutics For: Mar 07
-
Form 10-K Foghorn Therapeutics For: Dec 31
-
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
-
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-90
-
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
-
Form SC 13G/A Foghorn Therapeutics Filed by: FMR LLC
-
Form 8-K Foghorn Therapeutics For: Feb 08
-
Foghorn Therapeutics (FHTX) Provides Pipeline Update on FHD-909
-
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
-
Form 4 Foghorn Therapeutics For: Jan 24 Filed by: GOTTSCHALK ADRIAN
-
Form 4 Foghorn Therapeutics For: Jan 24 Filed by: Cavalie Fanny
-
Form 4 Foghorn Therapeutics For: Jan 24 Filed by: Cardama Alfonso Quintas
-
Form 4 Foghorn Therapeutics For: Jan 24 Filed by: Costa Carlos
-
Form 4 Foghorn Therapeutics For: Jan 24 Filed by: Bellon Steven F.
-
Form 4 Foghorn Therapeutics For: Jan 24 Filed by: LaCascia Michael
-
Foghorn Therapeutics (FHTX) Appoints Stephen J. DiPalma as Interim CFO
-
Form 8-K Foghorn Therapeutics For: Jan 16
-
Form 4 Foghorn Therapeutics For: Jan 16 Filed by: Reine Allan
-
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
-
Form 8-K Foghorn Therapeutics For: Jan 08
-
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
-
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
-
Flagship Pioneering Debuts Enabling Technologies Initiative
-
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
-
Form 8-K Foghorn Therapeutics For: Dec 29
-
Foghorn Therapeutics Inc. (FHTX) Announces CFO Departure
-
Foghorn Therapeutics Announces CFO Departure
-
Form 4 Foghorn Therapeutics For: Dec 08 Filed by: SMITH IAN F
-
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hemat
-
Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences
-
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
-
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
-
Foghorn Therapeutics (FHTX) PT Lowered to $6 at Morgan Stanley
-
Form 10-Q Foghorn Therapeutics For: Sep 30
-
Form 8-K Foghorn Therapeutics For: Nov 02
-
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
-
Flagship Pioneering Launches Pioneering Intelligence
-
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
Back to FHTX Stock Lookup
